NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CasInvent Pharma

CasInvent Pharma

Private
BrnoHealthcare & Life Scienceshttps://casinvent.com/

Last Round

Series A

Jul 2, 2025

Est. Valuation

$9M

Total Funding Raised

$7.37M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

CasInvent Pharma is a biotechnology company that develops selective small molecule inhibitors of casein kinase 1 (CK1) for the treatment of resistant tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

small-molecule inhibitorsdrug discoverycasein kinase 1CK1oncologybiotechcancer researchdrug resistancepreclinical developmenttherapeutic compoundspharma licensingAI-augmented drug discoverydrug pipelinebiotech spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CasInvent Pharma Comps

Public and private peers based on sector, stage, and business model.

CasInvent Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

CasInvent Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 2, 2025
VC RoundJul 2, 2025
GrantOct 1, 2024
SeedMay 28, 2024
Early FundingJan 30, 2024
Seed
Sep 13, 2022

Key People

Founding team and executive leadership

Alexander Scheer

Chief Executive Officer, Chief Scientific Officer

Executive Team

Vojtech Helikar

CFO COO, Board of Directors

Executive Team

CasInvent Pharma Investors

Notable investors and investment history

CasInvent Pharma investors
InvestorRounds
Garage AngelsSeed
i&i PragueEarly Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 291% MoM, from 107 to 418.

CasInvent Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CasInvent Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CasInvent Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrno
Employee Range7
Year Founded2020
Last FundingJul 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.